SCHEMBL20155667

SCHEMBL20155667

CCc1cccc(-n2ccnc2)c1OC

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 2/20 0.47
CYP11B1 P15538 2/20 0.47
CYP11B2 P19099 2/20 0.47
CYP1A2 P05177 7/20 0.45
CYP3A4 P08684 7/20 0.45
CYP2D6 P10635 7/20 0.45
CYP2C19 P33261 7/20 0.45
CYP2C9 P11712 4/20 0.45
GAA P10253 1/20 0.45
IDO1 P14902 2/20 0.44
ALDH1A1 P00352 4/20 0.41
TDP1 Q9NUW8 3/20 0.41
LMNA P02545 3/20 0.41
MAPT P10636 3/20 0.41
MAPK1 P28482 3/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
PMP22 Q01453 1/20 0.41
FGFR1 P11362 1/20 0.40
TP53 P04637 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3228422 0.82 IDO1 (0.58) CYP19A1CYP11B1CYP11B2CYP1A2CYP3A4
SCHEMBL24026460 0.79 CYP11B1 (0.49) CYP19A1CYP11B1CYP11B2CYP1A2CYP3A4
SCHEMBL20150092 0.77 ALOX15 (0.50) CYP19A1CYP11B1CYP11B2CYP1A2CYP3A4
SCHEMBL11077561 0.76 IDO1 (0.46) CYP19A1CYP11B1CYP11B2CYP1A2CYP3A4
SCHEMBL20155918 0.75 HCRTR1 (0.38) ALDH1A1MEN1KMT2AKDM4E
SCHEMBL12809226 0.75 LMNA (0.42) CYP19A1CYP11B1CYP11B2CYP1A2CYP3A4
SCHEMBL20155920 0.75 NPBWR1 (0.46) GAAALDH1A1LMNAMAPTMAPK1
Hydrochloric Acid SCHEMBL28581672 0.74 IDO1 (0.45) CYP19A1CYP11B1CYP11B2CYP1A2CYP3A4
SCHEMBL7114130 0.74 KDM4E (0.44) CYP19A1CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL20230855 0.73 NOTUM (0.47) CYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210094948-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-04-01 US disclosed
US-10647713-B2 TYK2 inhibitors and uses thereof NIMBUS LAKSHMI, INC. (US) 2020-05-12 US disclosed
US-10323036-B2 TYK2 inhibitors and uses thereof NIMBUS LAKSHMI, INC. (US) 2019-06-18 US disclosed
US-20180155349-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-06-07 US disclosed
US-20180134700-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210094948-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 CYP19A1 2724/4885CYP11B1 3696/4885CYP11B2 3385/4885
US-10323036-B2 TYK2 inhibitors and uses thereof TYK2, JAK2, JAK1 CYP19A1 2724/4885CYP11B1 3696/4885CYP11B2 3385/4885
US-20180134700-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 CYP19A1 2724/4885CYP11B1 3696/4885CYP11B2 3385/4885
US-20180155349-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 CYP19A1 2724/4885CYP11B1 3696/4885CYP11B2 3385/4885
US-10647713-B2 TYK2 inhibitors and uses thereof TYK2, JAK2, JAK1 CYP19A1 2724/4885CYP11B1 3696/4885CYP11B2 3385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.